Accessibility Menu
Comera Life Sciences logo

Comera Life Sciences(OTC) CMRA

Market Cap$3.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year-50%
1 Month+0%
$0.00
+0.00%
+0.00Today
Comera Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-31
Comera Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9,900%USD 0.002026-07-13
1 month+0%USD 0.002026-06-24
3 month+0%USD 0.002026-04-30
Year to date+9,900%USD 0.002025-12-31
1 year-50%USD 0.002025-07-31
3 year-99.98%USD 0.662023-08-01
5 year-100%USD 10.022021-07-30
Since inception-100%USD 10.022020-12-21

Comera Life Sciences Financials at a Glance

Market Cap

$3.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.00M

Net Income (TTM)

-$9.01M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

2932.52 (High)

Price

$0.00

Volume

400

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Nov 9, 2023

CMRA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Comera Life Sciences

Comera Life Sciences Holdings, Inc. is an early-stage biotechnology firm focused on developing innovative therapies. The company leverages its proprietary SQore formulation platform to convert intravenous biologic drugs into more convenient subcutaneous injectable forms.

Products and Services
  • CLS-001: A biobetter for treating inflammatory bowel conditions
  • CLS-002: A preclinical biobetter targeting various oncology indications
  • Exclusive SQore formulation platform for drug delivery
Growth Outlook
  • Pipeline includes two promising product candidates in development
  • Focus on addressing significant unmet medical needs in healthcare
  • Potential for strategic partnerships to enhance market reach
Financial Highlights
  • Q3 2023 revenue of 136,310, a decrease from Q2
  • Net income for Q3 2023 was -2,153,711, reflecting ongoing R&D investments
  • Cash and cash equivalents at 1,767,870 as of September 30, 2023
Comera Life Sciences Holdings, Inc. is positioned in the biotechnology sector, focusing on innovative drug delivery systems. The company is advancing its product pipeline, which includes CLS-001 and CLS-002, aimed at treating inflammatory bowel diseases and various cancers, respectively. The SQore formulation platform is a key differentiator, potentially transforming how biologic drugs are administered. Recent financial performance indicates challenges, with a notable decline in revenue from Q2 to Q3 2023. However, the company maintains a strong cash position, which may support ongoing research and development efforts. The focus on unmet medical needs and potential partnerships could provide avenues for future growth, making Comera Life Sciences an intriguing option for investors interested in the biotechnology landscape.
AI Generated • Jul 17, 2026

Industry

Biotechnology

Sector

Health Care

Employees

13

CEO

Jeffrey S Hackman

Website

comeralifesciences.com

Headquarters

Woburn, MA 01801, US

CMRA Financials

Key Financial Metrics (TTM)

Gross Margin

66.77%

Operating Margin

-1890.69%

Net Income Margin

-2843.79%

Return on Equity

47452.88%

Return on Capital

N/A

Return on Assets

-483.06%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

30.74M

Volume

400

Avg. Volume

949.968

Financials (TTM)

Gross Profit

$735.52K

Operating Income

-$9.15M

EBITDA

-$8.88M

Operating Cash Flow

-$6.66M

Capital Expenditure

-$28.68M

Free Cash Flow

-$35.34M

Cash & ST Invst.

$1.77M

Total Debt

$171.60K

Comera Life Sciences Performance Analysis

Comera Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 319,832N/A
20222022-12-31USD 633,10297.9%
Comera Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31-33.5%
Q12023-03-31151.7%
Q22023-06-30-19.8%
Q32023-09-30-56.7%
Comera Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -1.81N/A
20222022-12-31USD -1.76-2.8%
Comera Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-317.8%
Q12023-03-3129.5%
Q22023-06-3038.5%
Q32023-09-30-25.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

$136.31K

-42.0%

Gross Profit

$94.35K

-45.8%

Gross Margin

69.22%

N/A

Market Cap

$3.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$258.33

N/A

Employees

12

N/A

Net Income

-$2.15M

+30.0%

EBITDA

-$2.12M

+30.1%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Total Cash

$1.77M

-33.8%

Total Debt

$171.60K

-86.6%

Accounts Receivable

$100.00K

-66.0%

Inventory

$0.00

-100.0%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$171.60K

-84.5%

Return on Assets

-4.83%

N/A

Return on Invested Capital

8.99%

N/A

Free Cash Flow

-$1.91M

+20.7%

Operating Cash Flow

-$1.91M

+19.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNNAQSienna Biopharmaceuticals, Inc.
$0.00+0.00%
RBSHRebus Holdings, Inc.
$0.00+0.00%
SYVCSynovics Pharmaceuticals, Inc.
$0.00+0.00%
NLVVFNew Leaf Ventures Inc
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About CMRA

What is the current price of Comera Life Sciences?

Comera Life Sciences is trading at $0.00 per share.

What is the 52-week range for Comera Life Sciences?

Over the past 52 weeks, Comera Life Sciences has traded between $0.00 and $0.00.

How much debt does Comera Life Sciences have?

As of the most recent reporting period, Comera Life Sciences reported total debt of $775.05K.

How much cash does Comera Life Sciences have on hand?

Comera Life Sciences reported $1.95M in cash and cash equivalents in its most recent financial results.

What is Comera Life Sciences’s dividend yield?

Comera Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services